Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

Author(s): Grzegorz Korpanty, Elizabeth Smyth

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 19 , 2012

Become EABM
Become Reviewer

Abstract:

Tumour angiogenesis (formation of new blood vessels supporting tumour growth and metastasis) is a result of complex interactions between the tumour and the surrounding microenvironment. Targeting tumours with anti-angiogenic therapy remains an exciting area of preclinical and clinical studies. Although many significant advances have been achieved and the clinical use of anti-angiogenic drugs is now well recognized in many solid malignancies, these therapies fall short of their anticipated clinical benefits and leave many unanswered questions like exact mechanism of action, patients’ selection and monitoring response to anti-angiogenic drugs.

Tumour angiogenesis is controlled by complex signaling cascades and ongoing research into molecular mechanisms of tumour angiogenesis not only helps to understand its basic mechanisms but hopefully will identify new therapeutic targets.

In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies.

Keywords: Tumour angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, tyrosine kinase inhibitors, metastasis, microenvironment, solid malignancies, monoclonal antibodies, lymphatic vasculature, cytokines

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 19
Year: 2012
Page: [2680 - 2701]
Pages: 22
DOI: 10.2174/138161212800626166
Price: $65

Article Metrics

PDF: 14